Edition:
India

Zimmer Biomet Holdings Inc (ZBH.N)

ZBH.N on New York Stock Exchange

115.10USD
1:31am IST
Change (% chg)

$4.51 (+4.08%)
Prev Close
$110.59
Open
$109.16
Day's High
$115.23
Day's Low
$107.69
Volume
538,146
Avg. Vol
309,223
52-wk High
$133.45
52-wk Low
$104.28

Chart for

About

Zimmer Biomet Holdings, Inc. is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products. The Company's products... (more)

Overall

Beta: 1.18
Market Cap(Mil.): $24,115.91
Shares Outstanding(Mil.): 202.20
Dividend: 0.24
Yield (%): 0.80

Financials

BRIEF-Zimmer Biomet Reports Q1 Earnings Per Share $0.85

* ZIMMER BIOMET ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

26 Apr 2018

BRIEF-Zimmer Biomet Announces FDA Clearance And First Surgical Case Of The Persona Trabecular Metal Tibia

* ZIMMER BIOMET ANNOUNCES FDA CLEARANCE AND FIRST SURGICAL CASE OF THE PERSONA® TRABECULAR METAL™ TIBIA

17 Apr 2018

BRIEF-Zimmer Biomet Says CEO Hanson's FY'17 Total Compensation Was $16.3 Mln

* ZIMMER BIOMET SAYS CEO BRYAN HANSON'S FY 2017 TOTAL COMPENSATION WAS $16.3 MLN - SEC FILING

03 Apr 2018

BRIEF-Zimmer Biomet Holdings Files For Offering Of Floating Rate Notes Due 2021

* ZIMMER BIOMET HOLDINGS INC - FILES FOR OFFERING OF FLOATING RATE NOTES DUE 2021 AND NOTES DUE 2023 - SEC FILING Source text: (http://bit.ly/2tzlxYD) Further company coverage:

08 Mar 2018

BRIEF-Zimmer Biomet Holdings Reports Q4 EPS Of $6.16

* ZIMMER BIOMET ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2017 RESULTS

30 Jan 2018

BRIEF-Zimmer Biomet Holdings Announces FDA Clearance Of Sidus Stem-Free Shoulder System

* ZIMMER BIOMET HOLDINGS SAYS THE SIDUS SYSTEM WILL BE AVAILABLE IN U.S BEGINNING IN Q1 OF 2018 Source text for Eikon: Further company coverage:

04 Jan 2018

BRIEF-Zimmer Biomet Says Positive Results From Progress II Trial Of Autologous Protein Solution Prepared With nSTRIDE Aps Kit In Treating Osteoarthritis

* ZIMMER BIOMET HOLDINGS- POSITIVE RESULTS FROM PROGRESS II TRIAL OF AUTOLOGOUS PROTEIN SOLUTION PREPARED WITH NSTRIDE APS KIT IN TREATING OSTEOARTHRITIS Source text for Eikon: Further company coverage:

23 Dec 2017

BRIEF-Zimmer Biomet Names Bryan Hanson CEO

* ZIMMER BIOMET ANNOUNCES APPOINTMENT OF BRYAN C. HANSON AS PRESIDENT AND CHIEF EXECUTIVE OFFICER

19 Dec 2017

BRIEF-Zimmer Biomet Holdings Q3 adjusted earnings per share $1.72

* Q3 earnings per share view $1.74 -- Thomson Reuters I/B/E/S

01 Nov 2017

Competitors

Earnings vs. Estimates